Molecular structure of Sodium sulphobutylether-β-cyclodextrin, CAS Number: 182410-00-0
Sodium sulphobutylether-β-cyclodextrin (CAS 182410-00-0)
CAS Number:
182410-00-0
Molecular Weight:
2242.04
Molecular Formula:
C70H119O56S7•7Na
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Sodium sulphobutylether-β-cyclodextrin is a chemically modified derivative of β-cyclodextrin, designed to enhance the solubility and stability of poorly water-soluble compounds. β-cyclodextrins are cyclic oligosaccharides composed of glucose units linked by α-1,4 bonds, forming a torus-like structure with a hydrophilic exterior and a hydrophobic cavity. This unique structure enables cyclodextrins to form inclusion complexes with a wide range of guest molecules by encapsulating them within their hydrophobic core, thus improving their aqueous solubility. The sulphobutylether groups increase the hydrophilicity of the cyclodextrin, allowing it to dissolve more readily in water and interact more effectively with the encapsulated molecules.
Sodium sulphobutylether-β-cyclodextrin (CAS 182410-00-0) References
- Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. | von Mach, MA., et al. 2006. BMC Clin Pharmacol. 6: 6. PMID: 16981986
- Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. | Alvarez-Lerma, F., et al. 2008. J Chemother. 20: 93-100. PMID: 18343750
- Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia. | Zwitserloot, AM., et al. 2008. Pediatr Blood Cancer. 51: 423-6. PMID: 18478572
- Pharmacokinetics of antibiotics or antifungal drugs in intensive care units. | Dufour, G. and Montravers, P. 2009. Curr Infect Dis Rep. 11: 14-20. PMID: 19094820
- Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. | Salapatek, AM., et al. 2011. Allergy Asthma Proc. 32: 221-9. PMID: 21477425
- Optimizing antifungal choice and administration. | Andes, D. 2013. Curr Med Res Opin. 29 Suppl 4: 13-8. PMID: 23621589
- Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident? | Honore, PM., et al. 2015. Crit Care. 19: 234. PMID: 26013496
- Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. | Baden, LR., et al. 2016. J Natl Compr Canc Netw. 14: 882-913. PMID: 27407129
- Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial. | Breilh, D., et al. 2019. J Transl Int Med. 7: 155-169. PMID: 32010602
- Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. | Adamsick, ML., et al. 2020. J Am Soc Nephrol. 31: 1384-1386. PMID: 32513665
- Severe secondary hyperkalemia and arrhythmia from drug interactions between calcium-channel blocker and voriconazole: a case presentation. | Zhao, X., et al. 2021. BMC Nephrol. 22: 172. PMID: 33971831
- Comment about the safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin. | Wang, L. and Zhang, Z. 2022. Expert Opin Drug Saf. 21: 133-134. PMID: 34494496
- Not so rigid capsids based on cyclodextrin complexes: Keys to design. | Suárez-Lestón, F., et al. 2022. J Colloid Interface Sci. 623: 938-946. PMID: 35653855
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sodium sulphobutylether-β-cyclodextrin, 1 g | sc-483092 | 1 g | $214.00 | |||
Sodium sulphobutylether-β-cyclodextrin, 5 g | sc-483092A | 5 g | $520.00 |